Intermittent Cold Blood vs Crystalloid Cardioplegia in Aortic Valve Surgery
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Controversies still exists concerning the overall clinical effects of blood-based vs. crystalloid- based cardioplegic solution for myocardial protection during cardiac arrest. Both techniques are used world-wide. No larger prospectively randomized studies comparing the two methods have been reported. The aim of this study is to collect a large number of clinical data to create a proper basis for evaluation of the two techniques.
| Condition | Intervention |
|---|---|
|
Aortic Valve Disease Coronary Artery Disease |
Procedure: Myocardial protection techniques |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Intermittent Cold Blood vs Crystalloid Cardioplegia in Aortic Valve Surgery |
- Myocardial function,
- postoperative ventilatory support, postoperative arrhythmia,
- blood transfusions,
- physical recovery,
- mortality.
- Costs
| Estimated Enrollment: | 350 |
| Study Start Date: | November 2003 |
| Study Completion Date: | November 2007 |
| Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
All patients admitted for aortic valve replacement with or without concomitant CABG and operated by E.Ø. or G.T. are included in the study. All preoperative, operative and postoperative data are prospectively recorded, focusing on clinical outcome parameters
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Aortic valve replacement
Contacts and Locations
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00257777 History of Changes |
| Other Study ID Numbers: | AVR03, AVR03 |
| Study First Received: | November 22, 2005 |
| Last Updated: | July 3, 2011 |
| Health Authority: | Norway: Norwegian Medicines Agency Norway:The Data Inspectorate Norway Norway: Directorate of Health |
Additional relevant MeSH terms:
|
Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases |
Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases |
ClinicalTrials.gov processed this record on May 16, 2013